|
Evaluation of three disease management approaches to ESRD patient care (large pdf) |
 |
|
Summary (page 10): Overall, the ESRD Disease Management Demonstration appears to have resulted in some positive clinical benefits. Among the positive results found in this evaluation are that two of the three DMOs (DMO B and DMO C) showed higher survival at one and two years compared with FFS. Statistically significant reduction in all-cause and cardiovascular-related hospitalization were noted for DMO C compared with FFS. In addition, a specific process intervention (nutritional supplementation) was also directly associated with lower mortality among enrollees for DMO C. Some process of care measures improved, however results are mixed for other Disease Management process of care measures developed by the DMOs, due in part to problems with or changes in implementation, changes in protocol, and data limitations. Disease Management did not appear to have an impact on improving QoL for DMO enrollees at 12-month follow-up.
|